The Nellix endovascular aneurysm sealing system: current perspectives.

BACKGROUND: The Nellix endovascular aneurysm sealing (EVAS) system is a novel approach for the treatment of abdominal aortic aneurysm (AAA). We aimed to evaluate the efficacy of EVAS in the management of patients with AAA.
MATERIALS AND METHODS: We searched PubMed/MEDLINE, CINAHL, and bibliographic reference lists to identify studies reporting clinical outcomes in patients with asymptomatic, non-ruptured AAA treated with EVAS with the Nellix device. We pooled dichotomous outcome data using random-effects models.
RESULTS: We identified 14 single-arm observational studies, reporting a total of 1,510 patients. The pooled estimate of technical success was 99% (95% CI =98-100; heterogeneity: P=0.869, I 2=0%). Adjunctive procedures were carried out in 39% (95% CI =19-63; heterogeneity: P<0.0001, I 2=88%). Two cases of aneurysm rupture were reported within 30 days of treatment (0.7%, 95% CI =0.3-1.6; heterogeneity: P=0.923, I 2=0%) and another five cases of rupture occurred during follow-up (0.8%, 95% CI =0.4-1.6; heterogeneity: P=0.958, I 2=0%). The pooled estimates of early (within 30 days) and late (during follow-up) type I endoleak were 2.8 % (95% CI =1.8-4.2; heterogeneity: P=0.254, I 2=18%) and 1.9% (95% CI =1.3-2.8; heterogeneity: P=0.887, I 2=0%), respectively. Sac enlargement was noted in 3.1% (95% CI =1.8-5.4; heterogeneity: P=0.419, I 2=0%) and device migration in 2.1% (95% CI =0.8-5.3; heterogeneity: P=0.004, I 2=65%). The early and late reintervention rates were 2.7% (95% CI =1.7-4.2; heterogeneity: P=0.183, I 2=27%) and 3.5% (95% CI =2.3-5.5; heterogeneity: P=0.061, I 2=42%), respectively. The pooled estimate of 30-day mortality was 1.5% (95% CI =0.9-2.6; heterogeneity: P=0.559, I 2=0%) and the pooled estimate of aneurysm-related death during follow-up was 1.0% (95% CI =0.6-1.9; heterogeneity: P=0.872, I 2=0%).
CONCLUSION: Reported outcomes of EVAS are acceptable. Type I endoleak, sac enlargement, device migration, and aneurysm rupture are recognized complications. High-level research is required to investigate potential advantages of EVAS over conventional treatments.

Introduction

The Nellix system (Endologix Inc., Irvine, CA, USA) for endovascular aneurysm sealing (EVAS) is a novel approach to treatment of abdominal aortic aneurysm (AAA) and conceptually different from endovascular aneurysm repair (EVAR).1 EVAR was introduced in early 1990s and has now become an established treatment.2,3 The technique and devices have rapidly evolved and their application has expanded significantly.4,5

The EVAR procedure involves a stent-graft which is designed to exclude the aneurysm from the systemic circulation. The stent is made of a metallic skeleton and covered with polytetrafluoroethylene (PTFE) or polyester fabric which keeps the stent impermeable. The device is advanced through the femoral artery using fluoroscopic guidance toward the site of the aneurysm and then deployed. The aneurysm is isolated by sealing the proximal and distal ends of the aneurysm, preventing subsequent rupture.6

The Nellix device is designed to seal and obliterate the aneurysm lumen.1 It consists of two balloon-expandable stents which support the aorta flow channel. The system is introduced into the aorta in a similar way to EVAR; using guidewires, the system is advanced into the aorta through the femoral arteries. The catheter sheaths are then pulled back, deploying the device which expands from the non-aneurysmal aorta proximally to the iliac arteries distally. The non-porous PTFE-based endobags will then be filled using biocompatible polyethyleneglycol polymer, which adjusts the endobag to fit the aneurysm sac lumen. This allows sealing of the aneurysm and resists displacement.1

EVAS aims to overcome the shortcomings of EVAR as well as provide better clinical outcomes. The Nellix device received European CE Mark approval recently and is currently being monitored for efficacy.7 We aimed to conduct a comprehensive literature search and systematic review of published evidence to evaluate the efficacy of EVAS in the management of patients with AAA.

Materials and methods

Design

A prespecified protocol of the objectives and methods of the current systemic review was established. We reported this systematic review according to the PRISMA statement standards.

Patients of any gender and age.

Studies reporting clinical outcomes in series of patients with asymptomatic, non-ruptured AAA treated with EVAS with the Nellix device.

Articles written in English.

Case reports or case studies reporting less than five patients.

Editorials and letters to the editor or vascular images studies.

Review articles or experimental studies.

Articles that report clinical outcomes treated with other vascular devices.

Outcome measures

Outcome parameters were technical success, procedure time, fluoroscopy time, need for adjunctive procedures, mortality, postoperative complications, rupture of AAA, endoleak, device migration, sac enlargement, reintervention, and length of hospital stay.

Search strategy

Studies included in this review were identified through a focused search of the electronic databases PubMed/MED-LINE and CINAHL. The keywords used were “Nellix” and “endovascular aneurysm sealing”. The last search was conducted in April 2018. We also searched the bibliographic lists of relevant articles and reviews for further potentially eligible studies. Finally, we hand-searched the following leading journals in vascular and endovascular surgery: Journal of Vascular Surgery, European Journal of Vascular and Endovascular Surgery, and Journal of Endovascular Therapy.

Data collection

We created an electronic data extraction spreadsheet, pilot-tested it in randomly selected articles, and adjusted it accordingly. Our data extraction spreadsheet included the following information:

Study-related data: prospective or retrospective study design, type of study (case series or cohort study), year of publication, recruitment period, country of corresponding author, case type (single- or multicenter), and inclusion and exclusion criteria.

Baseline demographic and clinical characteristics of the study populations: age, gender, American Society of Anesthesiologists grade, smoking history, hypertension, diabetes, cardiac disease, respiratory disease, cerebrovascular disease, and renal disease.

Aneurysm anatomic data: aneurysm maximum diameter; aortic neck diameter, length and angulation; and whether the device was used within recommended instructions for use (IFU).

Outcome data.

Two authors independently collected and recorded data in the data extraction spreadsheet. Disagreements were resolved by discussion. If no agreement could be reached, a third author was consulted.

Data synthesis

We used simple descriptive statistics to present demographic and clinical data. We used the method of conversion from median to mean that was recommended by Hozo et al.38 We pooled categorical outcome data in the entire review population by meta-analyzing data from individual studies. The pooled proportion was calculated as the back transformation of the weighted mean of the transformed proportions. We anticipated considerable clinical between-study heterogeneity and, therefore, applied random-effects models. We examined heterogeneity with the combination of the Cochran’s Q (χ2) test and the I2 statistic. We used the Comprehensive Meta-Analysis software (Biostat, Englewood, NJ, USA).

Results

Results of literature search

Search of electronic databases identified a total of 634 articles (Figure 1). Following assessment of titles and abstracts, 395 articles were excluded as they were not relevant to the subject of this study. Following further evaluation, 201 articles were excluded. The full texts of the remaining 38 articles were obtained and assessed for eligibility. Fourteen studies met the inclusion criteria of our study and were included in qualitative and quantitative synthesis.8–21

Figure 1

Flowchart demonstrating the literature search strategy.

Study characteristics

Table 1 presents study-related information. Baseline demographic and clinical characteristics of the study populations are summarized in Table 2. All 14 articles were single-arm observational studies and were published after 2011. The recruitment period in all but one study was 1 year or more.17 Four studies10,12,13,16 reported 1-year outcomes, while the remaining studies reported longer follow-up outcomes.8,9,11,14,15,18–21 The weighted mean follow-up was 11.6±5.4 months. Nine studies8,9,11,13,16–19,21 were multicenter studies and the remaining five were single-center studies.10,12,14,15,20

Table 1

Study characteristics

First author, year	Study period/design	Country of the corresponding author	Case type	Study design	Inclusion criteria	Exclusion criteria
Krievins et al, 20118	2008–2010/P	USA	M	Case series	Patients with one or more of the following: aneurysm size 4.5 cm or greater, aneurysm size twice the diameter of the infrarenal neck, and documented rate of aneurysm enlargement >10% in 1 year with aortic neck length 10 mm or greater. After review of the clinical results from the first 21 patients, the study protocol was modified to allow inclusion of patients with shorter aortic necks (5 mm or greater)	NR
Donayre et al, 20119	2007–2009/R	USA	M	Case series	All patients appropriate for open aortic aneurysm repair with suitable anatomy for endovascular repair using the sac-anchoring endoprosthesis	Patients with iliofemoral arteries unable to accommodate a 21F outer diameter delivery catheter
Zerwes et al, 201510	July 2013–August 2014/R	Germany	S	Case series	One or more of the following: aortic aneurysm size 50 mm or larger, symptomatic (non-ruptured) aneurysms, documented aneurysm enlargement of 5 mm in 6 months or 10 mm in 1 year, and common iliac artery aneurysm size of 25 mm or larger	NR
Böckler et al, 201511	October 2012–March 2014/R	Germany	M	Case series	Consecutively treated patients who underwent AAA repair with the Nellix EVAS device subsequent to CE marking were included in this study	NR
Brownrigg et al, 201512	March 2013–April 2014/R	UK	S	Case series	All patients with non-ruptured infrarenal AAA treated with the Nellix device	NR
Carpenter et al, 201613	2015–2016/P	USA	M	Case series	All patients with AAA of the following clinical characteristics: male or female, at least 18 years old, AAA >5.0 cm, or >4.5 cm which has increased by >0.5 cm within the last 6 months, or which exceeds 1.5 times the transverse dimension of an adjacent non- aneurysmal aortic segment, asymptomatic infrarenal AAA, with access artery diameter ≥6 mm, aneurysm blood lumen diameter ≤60 mm, non-aneurysmal aortic neck length ≥10 mm and ≤60° angle and lumen diameter 18–32 mm, common iliac artery blood lumen diameter 9–35 mm, most caudal renal artery to each hypogastric artery length ≥100 mm, and the ability to preserve at least one hypogastric artery	Patients with life expectancy <2 years, condition that may interfere with study, participating in another clinical study, known allergies or CI to any device material, bleeding disorder, ruptured/leaking/infected aneurysm, Serum creatinine level >2.0 mg/dL, CVA or MI ≤3 months of enrollment/treatment, aneurysmal disease of the descending thoracic aorta, clinically significant mural thrombus within the proximal landing zone (minimum 10 mm) of the infrarenal non-aneurysmal neck (>5 mm thickness over >50% circumference), connective tissue diseases, pregnant
Karouki et al, 201614	2013–2015/R	UK	S	Cohort study	All patients treated with EVAS in the institution	NR
van Sterkenburg et al, 201615	June 2013–May 2015/R	The Netherlands	S	Case series	Patients who were treated with Nellix for an aneurysm in conjunction with iliac artery occlusive disease were selected	NR
Thompson et al, 201616	October 2013–September 2014/R	UK	M	Case series	All patients who were treated with the Nellix EVAS system for non-ruptured AAAs, irrespective of whether the aortic anatomy conformed to the Nellix IFU	Ruptured AAA, failing bifurcated endograft, or isolated iliac aneurysm
Silingardi et al, 201617	September 2013–July 2014/R	Italy	M	Case series	Patients were eligible for endovascular repair with an infrarenal AAA >5 cm in axial diameter or with rapid growth (>1 cm in the last 12 months), all procedures performed at least 12 months prior to the analysis were included	NR
Youssef et al, 201618	May 2013–June 2015/R	Germany	M	Case series	Patients with common iliac artery aneurysms who underwent implantation of Nellix device	NR
Gossetti et al, 201719	September 2013–November 2015/R	Italy	M	Cohort study	Patients presenting with juxtarenal or infrarenal aortic aneurysm requiring elective treatment, AAA diameter ≥4.5 cm, and AAA enlargement >1 cm within the previous year	NR
Jeffrey Hing et al, 201820	July 2014–August 2016/R	Singapore	S	Case series	All patients treated with EVAS, by the same group of vascular team	NR
Zoethout et al, 201821	April 2013–December 2015/R	The Netherlands	M	Case series	All patients treated with first-generation Nellix, inside the IFU of 2013 and 2016a	Symptomatic or ruptured AAA, missing CT scan, patients who were not treated with a regular EVAS procedure

Notes:

Data reported in Tables 2–6 are outcomes of cohort which fit within IFU 2013.

Abbreviations: AAA, abdominal aortic aneurysm; CI, contraindication; CT, computed tomography; CVA, cerebrovascular accident; EVAS, endovascular aneurysm sealing; IFU, instruction for use; M, multicenter; MI, myocardial infarction; NR, not reported; P, prospective; R, retrospective; S, single.

Table 2

Baseline demographics and clinical characteristics of the study population

First author, year	No. of patients	Male, n (%)	Age, yearsa	ASA grade and type, n (%)	Smoking history, n (%)	HTN, n (%)	DM, n (%)	CAD, n (%)	Angina, n (%)	MI, n (%)	AR, n (%)	CHF, n (%)	COPD, n (%)	CVD, n (%)	CKD, n (%)
Krievins et al, 20118	34	31 (91)	71 (53–84)	NR	17 (50)	23 (68)	4 (12)	19 (56)	NR	9 (27)	NR	NR	NR	NR	1 (3)
Donayre et al, 20119	21	19 (91)	70±8 (53–84)	NR	12 (57)	15 (71)	2 (10)	11 (52)	NR	11 (52)	NR	NR	NR	NR	1 (5)
Zerwes et al, 201510	50	43 (86)	72 (59–90)	ASA I: 0; ASA II: 19 (38); ASA III: 23 (46); ASA IV: 8 (16)	34 (68)	49 (98)	12 (24)	30 (60)	NR	13 (26)	NR	NR	7 (14)	NR	6 (12)
Böckler et al, 201511	171	153 (90)	74±7	ASA I: 2 (1); ASA II: 57 (34); ASA III: 79 (47); ASA IV: 30 (18)	77 (49)	130 (76)	15 (9)	27 (16)	41 (24)	54 (32)	33 (19)	15 (9)	47 (28)	18 (11)	32 (19)
Brownrigg et al, 201512	105	92 (88)	76±8	NR	74 (71)	82 (78)	13 (12)	36 (34)	NR	NR	NR	NR	NR	NR	13 (12)
Carpenter et al, 201613	150	142 (95)	73	ASA I/II: 41 (27); ASA III: 92 (61); ASA IV: 17 (11)	78 (58)	123 (82)	26 (17)	76 (51)	16 (11)	38 (25)	42 (28)	NR	41 (27)	18 (14)	24 (16)
Karouki et al, 201614	65	49 (75)	78±7	NR	48 (75)	56 (86)	8 (12)	NR	NR	NR	NR	NR	18 (28)	NR	15 (23)
van Sterkenburg et al, 201615	5	3 (60)	NR	NR	3 (60)	3 (60)	1 (20)	NR	NR	3 (60)	NR	NR	NR	2 (40)	NR
Thompson et al, 201616	277	228 (82)	75±7	ASA I: 6 (2); ASA II: 93 (34); ASA III: 149 (51); ASA IV: 35 (13)	145 (52)	208 (75)	47 (17)	120 (43)	53 (19)	70 (25)	48 (17)	20 (7)	75 (27)	21 (8)	53 (19)
Silingardi et al, 201617	64	61 (95)	77±7	ASA II: 19 (30); ASA III/IV: 29 (45); ASA V: 1 (2)	38 (59)	55 (86)	9 (14)	19 (30)	NR	16 (25)	NR	NR	29 (45)	NR	8 (13)
Youssef et al, 201618	50	35 (70)	76 (59–86)	ASA III: 25 (50); ASA IV: 6 (12)	42 (84)	40 (80)	10 (20)	29 (58)	NR	NR	NR	NR	20 (40)	NR	NR
Gossetti et al, 201719	335	316 (94)	76±7	ASA I: 2 (1); ASA II: 43 (13); ASA III: 209 (62); ASA IV: 81 (24)	227 (68)	211 (63)	84 (25)	134 (40)	70 (21)	97 (29)	NR	NR	147 (44)	56 (17)	79 (24)
Jeffrey Hing et al, 201820	15	15 (100)	73±8 (55–85)	ASA II: 3 (20); ASA III: 12 (80)	8 (53)	13 (87)	3 (20)	NR	NR	NR	NR	NR	3 (20)	NR	NR
Zoethout et al, 201821	168	155 (92)	74	ASA II: 107 (64); ASA ≥III: 60 (36); missing information: 1 (1)	78 (46)	112 (67)	27 (16)	NR	NR	NR	NR	NR	47 (28)	NR	34 (20)

Note:

Mean ± SD (range).

Abbreviations: AR, arrhythmia; ASA, American Society of Anesthesiologists physical status classification; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; CVD, cerebrovascular disease; DM, diabetes mellitus; HTN, hypertension; MI, myocardial infarction; NR, not reported.

The included studies reported a total of 1,510 patients with asymptomatic, non-ruptured AAA treated with EVAS with the Nellix device. The weighted mean age of the included patients was 74±2 years and 89% of the patients were male. Hypertension was the most common comorbidity (74%), followed by cardiac disease (coronary artery disease 40%, myocardial infarction 28%, arrhythmia 21%, angina 19%, congestive cardiac failure 8%), respiratory disease (32%), renal disease (19%), diabetic mellitus (17%), and cerebrovascular disease (12%). Smoking was present in 58% of the patients.

The inclusion criteria varied among the studies. The specific inclusion criteria for each of the selected studies are summarized in Table 1. van Sterkenburg et al described the outcomes of EVAS using the Nellix device in patients with associated iliac artery occlusive disease.15 Youssef et al investigated the outcomes of EVAS with the Nellix endoprosthesis in patients with AAA and/or common iliac artery aneurysm.18 Zoethout et al reported the outcomes of patients based on the recommended IFU 2013 and IFU 2016.21

Aneurysm anatomic characteristics

Table 3 presents the aneurysm anatomic characteristics. Most authors reported anatomic data of the aneurysm and whether the aneurysm was treated within the IFU 2013. Eighty percent of the included patients had their aneurysm treated within the IFU for the Nellix device. The weighted mean maximum aneurysm diameter was 60±6 mm. The weighted mean aortic neck diameter and length were 24±2 and 25±4 mm, respectively. The mean angulation of the aortic neck was 32°±9°.

Table 3

Aneurysm anatomic data

First author, year	Treatment within IFU, n (%)	Aneurysm maximum diameter, mma	Aortic neck diameter, mma	Aortic neck length, mma	Aortic neck angulation (°)a
Krievins et al, 20118	17 (50)	58 (34–76)	24 (18–31)	22 (5–50)	37 (9–72)
Donayre et al, 20119	NR	57±0.7 (43–74)	26±3.7 (16–28)	25±14 (0–59)	39±15 (10–66)
Zerwes et al, 201510	36 (72)	56±7.2 (38–74)	24±3.9 (18–34)	28±13 (10–65)	18±23
Böckler et al, 201511	116 (67)	61±9	25±5	28±15	37±22
Brownrigg et al, 201512	NR	61 (58–67)	27 (24–30)	22 (14–33)	42 (30–58)
Carpenter et al, 201613	NR	58±6.2 (44–82)	25±3 (19–32)	31±14 (10–103)	30±14 (3.3–59)
Karouki et al, 201614	43 (66)	77±28b	28±5.1	26±15	30 (0–78)
van Sterkenburg et al, 201615	5 (100)	57±4b	20±2b	23±11b	NR
Thompson et al, 201616	200 (72)	60±1.7b	25±0.9b	24±4b	31±4.5b
Silingardi et al, 201617	53 (83)	57±9.3	22±3.3	27±12	17±19
Youssef et al, 201618	NR	NR	NR	NR	NR
Gossetti et al, 201719	295 (88)	56±9.4 (45–65)	23±3.5 (20–24)	26±15 (15–35)	41±27 (14–68)
Jeffrey Hing et al, 201820	11 (70)	64±167 (41–100)	22 (15–38)	29 (1–64)	42 (10–80)
Zoethout et al, 201821	168 (100)	58±1.2b	23±0.6b	18±3.2b	22±3.7b

Notes:

Mean ± SD (range).

These data are reported in median with range and/or IQR. The presented value in the table is the mean value after conversion from median to mean using Hozo et al’s suggested method.38

Abbreviations: IFU, instructions for use; NR, not reported.

Clinical outcomes

Outcome data are presented in Tables 4–6.

Table 4

Surgical data

First author, year	Anesthesia, n (%)	Technical success, %	Procedure time, minutesa	Fluoroscopy time, minutesa	Adjunctive procedures, n (%)	Details about adjunctive procedures	Post-op complications, n (%)	Type of complication
Krievins et al, 20118	NR	100	70±32	33±17 (17–71)	NR	NR	NR	NR
Donayre et al, 20119	NR	100	127 (80–148)	33±17	NR	NR	NR	NR
Zerwes et al, 201510	NR	98	101±20	NR	NR	NR	3 (6)	Partial endograft limb thrombosis, retroperitoneal hematoma with prolapse of endobag with low-flow endoleak type Ia, endoleak type II
Böckler et al, 201511	NR	99	100 (25–286)	11±11b	NR	NR	NR	NR
Brownrigg et al, 201512	NR	100	NR	NR	62 (59)	62 adjunctive iliac stentings	NR	NR
Carpenter et al, 201613	GA: 84 (56); LA: 66 (44)	100	88 (50–205)	10	NR	NR	2 (1.3)	Delayed filling of the renal artery, intraoperative iatrogenic AAA rupture during the prefill step
Karouki et al, 201614	NR	100	NR	NR	5 (7.7)	Five iliac stents	6 (9.2)	Groin hematoma, T1RF, occlusion due to cancer-induced thrombophilia, paraparesis, popliteal embolus, hemispheric stroke
van Sterkenburg et al, 201615	GA: 4 (80); LA: 1 (20)	100	NR	NR	2 (40)	One thrombo- endarterectomy, one chimney graft	3 (60)	Groin hematoma, duodenal bleeding, occlusion of femoral artery
Thompson et al, 201616	NR	NR	98±7b	11±1b	NR	NR	NR	NR
Silingardi et al, 201617	GA: 40 (63); LA: 24 (38)	98	97±30 (56–182)	8±2	NR	NR	0	0
Youssef et al, 201618	GA: 30 (60); LA: 20 (40)	100	151±45	NR	30 (60)	30 iliac stents	3 (6)	Inguinal hematoma, wound infection, respiratory failure
Gossetti et al, 201719	GA: 153 (46); RA: 21 (6); LA: 161 (48)	100	101	NR	NR	NR	2 (0.6)	Two incidental hypogastric artery occlusions
Jeffrey Hing et al, 201820	GA: 12 (80); RA: 1 (7); LA: 2 (13)	100	139	NR	6 (40)	Three open-access endarterectomies with embolectomy, one coil embolization of internal iliac artery, one bilateral renal artery chimneys, one proximal stent deployment	6 (40)	One severe T1RF, five post- implantation syndrome
Zoethout et al, 201821	GA: 143 (85); RA: 25 (15)	98	90±6b	NR	NR	NR	3 (1.8)	Three type Ia endoleaks

Notes:

Mean ± SD (range) unless stated otherwise.

These data are reported in median with range and/or IQR. The presented value in the table is the mean value after conversion from median to mean using Hozo et al’s suggested method.38

Abbreviations: GA, general anesthesia; LA, local anesthesia; NR, not reported; RA, regional anesthesia; T1RF, type 1 respiratory failure.

Table 5

Early clinical outcomes (within 30 days)

First author, year	Length of hospital stay, daysa	Presence of endoleak, n (%)	Aneurysm rupture, n (%)	Sac enlargement, n	Device migration, n	Reintervention, n (%)	In-hospital or 30-day mortality (non-device related), n (%)	In-hospital or 30-day mortality (aneurysm/device related), n (%)
Krievins et al, 20118	3.8±2.2 (1–9)	Type IA: 2 (5.9)	0	NR	NR	1 (2.9)	0	1 (2.9)
Donayre et al, 20119	4.3 (2–11)	Type I: 2 (9.6)	NR	NR	NR	0	1 (4.8)	0
Zerwes et al, 201510	9.9±5.4 (4–24)	Type IA: 1 (2), type II: 1 (2)	1 (2.0)	0	0	NR	2 (4)	0
Böckler et al, 201511	NR	Type IA: 3 (2), type IB: 3 (2), type II: 3 (2)	0	NR	0	11 (6.4)	0	0
Brownrigg et al, 201512	2±0.5b	Type IA: 4 (3.8)	0	NR	NR	3 (2.9)	1 (1)	0
Carpenter et al, 201613	NR	Type IA: 1 (0.7), type II: 8 (5.6)	0	NR	NR	NR	NR	2 (1.3)
Karouki et al, 201614	NR	0	0	NR	NR	2 (3.1)	0	NR
van Sterkenburg et al, 201615	NR	0	NR	0	NR	0	0	NR
Thompson et al, 201616	4b	Type IA: 8 (2.9), type IB: 1 (0.4), type II: 5 (1.8)	1 (0.4)	NR	NR	3 (1.1)	3 (1.1)	0
Silingardi et al, 201617	3.3±4.6 (1–35)	0	0	0	0	0	0	0
Youssef et al, 201618	8±3.5b	0	NR	NR	NR	NR	0	0
Gossetti et al, 201719	NR	Type IA: 1 (0.3), type II: 2 (0.6)	NR	NR	1 (0.3)	6 (1.8)	0	0
Jeffrey Hing et al, 201820	2b	0	NR	0	1 (6.7)	0	0	0
Zoethout et al, 201821	NR	Type I: 3 (1.8), type II: 1 (0.6)	NR	0	NR	3 (1.8)	NR	NR

Notes:

Mean ± SD (range) unless stated otherwise.

These data are reported in median with range and/or IQR. The presented value in the table is the mean value after conversion from median to mean using Hozo et al’s suggested method.38

Abbreviation: NR, not reported.

Table 6

Late clinical outcomes (during follow-up)

First author, year	Length of follow-up, monthsa	Aneurysm surveillance protocol	Presence and type of endoleak, n (%)	Aneurysm rupture, n (%)	Sac enlargement, n (%)	Stent migration, n (%)	Reintervention, n (%)	Aneurysm- related mortality, n (%)	Overall mortality, n (%)
Krievins et al, 20118	15±6	Follow-up CT scans performed at 6, 12, and 24 months	Type IA: 1 (3.1)	0	0	0	1 (2.9)	0	2 (5.9)
Donayre et al, 20119	7.3±10	Clinical results and follow-up contrast CT scans at 30 days and 6 and 12 months were reviewed	0	0	NR	0	0	0	2 (9.6)
Zerwes et al, 201510	NR	Contrast-enhanced ultrasound after 3 and 6 months and with CT scans after 12 months	0	0	0	0	NR	0	2 (4)
Böckler et al, 201511	5 (0–14)	30-day and 1-year postoperative CT imaging studies and a duplex ultrasound examination at 6 months	Type IA: 2 (2), type IB: 1 (1), type II: 1 (1)	0	NR	0	5 (2.9)	0	1 (2)
Brownrigg et al, 201512	1	Postoperative duplex and CTA prior to discharge and within 30 days at 6 and 12 months and yearly thereafter	0	0	NR	NR	NR	NR	0
Carpenter et al, 201613	12	CTA scans at 30 days, 6 months, and 1 year	Type IA: 0, type IB: 1 (0.8), type II: 3 (2.3)	2 (1.3)	2 (1.3)	3 (2.3)	5 (3.3)	2 (1.3)	6 (4)
Karouki et al, 201614	12 (0–24)	Contrast-enhanced CT and unenhanced duplex ultrasound at 1 month and yearly thereafter	0	0	NR	NR	2 (3.1)	0	1 (1.5)
van Sterkenburg et al, 201615	8.5±3.5b	Clinical assessment, duplex ultrasound, and CTA at 6–8 weeks; clinical assessment and duplex at 6 months; and clinical assessment, duplex ultrasound, and CTA at 12 months and yearly thereafter	0	NR	NR	NR	0	0	0
Thompson et al, 201616	12	Clinical assessment and imaging follow-up with high-resolution contrast-enhanced CT scans and/or duplex ultrasound	Type IA: 4 (1.4), type III: 1 (0.4)	2 (0.8)	NR	NR	5 (1.8)	1 (0.4)	11 (4)
Silingardi et al, 201617	17b	Clinical examination with duplex imaging at 30 days and CTA at 3 months after the procedure in both centers. Thereafter, one center used duplex and the other used CTA surveillance imaging at 6 and 12 months	Type IA: 1 (1.6), type II: 1 (1.6)	0	0	0	1 (1.6)	1 (1.6)	4 (6.2)
Youssef et al, 201618	12±4.8b	Physical examination (pulse status and ankle–brachial index), duplex sonography, and CTA at discharge, 6 and 12 months, and yearly thereafter	0	NR	NR	NR	0	0	2 (4)
Gossetti et al, 201719	12	Duplex ultrasound or contrast-enhanced ultrasound examination before discharge and at 1, 6, 12, and 24 months	Type IA: 4 (1.4), type IB: 2 (0.7), type II: 3 (1.1)	0	NR	2 (0.7)	12 (3.7)	2 (0.6)	19 (5.6)
Jeffrey Hing et al, 201820	14 (2–28)	CTA at 1, 6, 12 months, and annually thereafter	Type IB: 1 (7)	0	0	2 (13)	0	0	3 (20)
Zoethout et al, 201821	23±2.3b	CTA at 1–3 and 12 months, and annually thereafter if stable	Type I: 5 (3)	1 (0.6)	8 (4.8)	12 (7.1)	16 (9.5)	NR	14 (8.3)

Notes:

Mean ± SD (range) unless stated otherwise.

These data are reported in median with range and/or IQR. The presented value in the table is the mean value after conversion from median to mean using Hozo et al’s suggested method.38

Abbreviations: CT, computed tomography; CTA, computed tomographic angiography; NR, not reported.

Technical success

Technical success was reported by 13 studies (1,233 patients).8–15,17–21 The technical success rate ranged from 98% to 100%. Technical success was achieved in 1,226 out of 1,233 patients with a pooled estimate of 99% (95% CI =98–100; heterogeneity: P=0.869, I2=0%).

Procedure time

Eleven studies (1,335 patients) reported the procedure time which ranged from 70 to 151 minutes.8–11,13,16–21 The weighted mean procedure time was 106±24 minutes.

Fluoroscopy time

The fluoroscopy time ranged from 8 to 33 minutes across 6 studies (717 patients).8,9,11,13,16,17 The weighted mean was 17±12 minutes.

Adjunctive procedures

Five studies reported data on adjunctive procedures.12,14,15,18,20 Adjunctive procedures were carried out in 105 out of 240 patients (pooled estimate 39%, 95% CI =19–63; heterogeneity: P<0.0001, I2=88%), with a rate ranging from 7.7% to 60%. These included 97 cases of adjunctive iliac stenting, 4 cases of femoral endarterectomy, 2 cases of chimney grafts, 1 case of coil embolization of internal iliac artery, and 1 case of additional proximal stenting.

Postoperative complications

Nine studies (902 patients) reported data on postoperative complications.10,13–15,17–21 The incidence of postoperative complications ranged from 0% to 60% across the nine studies and the pooled estimate was 5.6% (95% CI =1.9–15.2; heterogeneity: P<0.0001, I2=86%). Complications included endoleak,10,21 wound infection,18 thrombus formation in the endograft,10 groin hematoma,14,15,18 occlusion of the femoral artery15 or the hypogastric arteries,19 embolus formation,14 duodenal bleeding,15 and respiratory failure.14,18,20 Karouki et al reported one case of paraparesis.14 Jeffrey Hing et al reported five cases with post-implantation syndrome.20

Aneurysm rupture

Rupture of AAA within 30 days of the procedure was reported in eight studies (916 patients), with a rate ranging from 0% to 2% and a pooled estimate of 0.7% (95% CI =0.3–1.6; heterogeneity: P=0.923, I2=0%).8,10–14,16,17 Only two ruptures occurring within 30 days were noted in two studies, one case in each.10,16 Over a follow-up ranging from 1 to 23 months, 12 studies reported 5 cases of ruptured AAA (out of 1,455 patients), with an incidence ranging from 0% to 1.3% and a pooled estimate of 0.8% (95% CI =0.4–1.6; heterogeneity: P=0.958, I2=0%).8–14,16,17,19–21

Length of hospital stay

Eight studies (616 patients) reported data on the length of hospital stay, which ranged from 1 to 9 days.8–10,12,16–18,20 The weighted mean length of hospital stay was 5±3 days.

Endoleak

All included studies reported endoleak as an outcome. Forty-nine out of 1,510 patients were reported with endoleak within 30 days of the procedure, with a rate ranging from 0% to 9.6% across the studies.8–13,16,19,21 Around half of the endoleaks noted (29, 59%) were type I and the remaining were type II. The pooled estimate of early (within 30 days) type I endoleak was 2.8% (95% CI =1.8–4.2; heterogeneity: P=0.254, I2=18%) and that of early type II endoleak was 1.9% (95% CI =1.2–3.0; heterogeneity: P=0.266, I2=17%). During a follow-up ranging from 1 to 23 months, all 14 studies (1,510 patients) reported cases of endoleak, with an incidence ranging from 0% to 3.1%. Six studies found no endoleaks during follow-up.9,10,12,14,15,18 The remaining eight studies found a total of 31 endoleaks.8,11,13,16,17,19–21 The most common type of endoleak was type I (22 counts), followed by type II (8 counts) and type III (1 count). The pooled estimate of type I endoleak was 1.9% (95% CI =1.3–2.8; heterogeneity: P=0.887, I2=0%), that of type II endoleak was 1.1% (95% CI =0.7–2.0; heterogeneity: P=0.871, I2=0%), and the pooled estimate of type III endoleak was 0.7 (95% CI =0.4–1.5; heterogeneity: P=0.847, I2=0%).

Sac enlargement

Five studies (302 patients) reported sac enlargement within 30 days.10,15–17,20 None of the studies found sac enlargement occurring within 30 days of the procedure. During follow-up ranging from 12 to 23 months, six studies evaluated aneurysm sac enlargement, with an incidence ranging from 0% to 5%.8,10,13,17,20,21 It was noted that 10 patients out of a total of 481 had aneurysm sac enlargement shared between two studies, with one study reporting 2 cases of sac enlargement and the other reporting 8 cases.13,21 The four remaining studies did not find any sac enlargement during follow-up.8,10,17,20 The pooled estimate of the incidence of sac enlargement was 3.1% (95% CI =1.8–5.4; heterogeneity: P=0.419, I2=0%).

Device migration

Five studies reported data on device migration that occurred within 30 days of surgery, with a rate ranging from 0% to 6.7% across the studies and a pooled estimate of 0.9% (95% CI =0.3–3.3; heterogeneity: P=0.211, I2=32%).10,11,17,19,20 Only 2 out of 635 patients were noted with device migration within 30 days. During a follow-up ranging from 5 to 23 months, nine studies reported the incidence of device migration which ranged from 0% to 13% and the pooled esti mate was 2.1% (95% CI =0.8–5.3; heterogeneity: P=0.004, I2=65%).8–11,13,17,19–21 Nineteen out of a total of 1,008 patients were found to have migration of the Nellix device during follow-up.13,19–21

Reintervention

Reintervention within 30 days of the procedure was reported in 29 out of 1,260 patients, with a rate ranging from 0% to 6.4% across eleven studies and a pooled estimate of 2.7% (95% CI =1.7–4.2; heterogeneity: P=0.183, I2=27%).8,9,11,12,14–17,19–21 During a follow-up period of 5–23 months, 47 out of 1,355 patients had reintervention, with a rate ranging from 0% to 9.5% across 12 studies and a pooled estimate of 3.5% (95% CI =2.3–5.5; heterogeneity: P=0.061, I2=42%).8,9,11,13–21

Mortality

Mortality within 30 days of surgery was reported by 13 studies, with a rate ranging from 0% to 4.8% across the studies and a pooled estimate of 1.5% (95% CI =0.9–2.6; heterogeneity: P=0.559, I2=0%).8–20 Ten deaths out of 1,342 patients occurred within 30 days. Seven out of ten deaths (70%) were non-aneurysm/device related. Seven out of 13 studies reported zero 30-day mortality.11,14,15,17–20 Mortality during follow-up was reported by all 14 studies.8–21 The follow-up period ranged from 1 to 23 months. Overall, 67 deaths (out of 1,510 patients) were reported during follow-up, with a mortality rate ranging from 0% to 20% across the studies. The pooled estimate for mortality during follow-up was 5.2% (95% CI =3.7–7.3; heterogeneity: P=0.076, I2=38%). Six of the 67 deaths (9%) were found to be aneurysm related. The pooled estimate of aneurysm-related death during follow-up was 1.0% (95% CI =0.6–1.9; heterogeneity: P=0.872, I2=0%).

Discussion

We conducted a systematic review and identified 14 single-arm observational studies, reporting a total of 1,510 patients who underwent repair for an asymptomatic, non-ruptured AAA with EVAS using the Nellix device. Our review demonstrated that, despite the wide range of aneurysm morphologies among and within the included studies, treatment with the Nellix device was associated with a high a technical success rate ranging from 98% to 100%. Most authors defined technical success as successful deployment of the device to exclude the aneurysmal flow and absence of endoleak or stent thrombosis on completion of angiography.8–15,17–19,21 Interestingly, technical success of an aneurysm with a proximal neck angulation of 80° was reported in a patient treated outside the IFU for the Nellix device.20 The rate of postoperative complications ranged widely from 0% to 60% across nine studies, reflecting the variability in reporting perioperative morbidity among the studies.10,13–15,17–21 We found that the weighted mean procedure time and length of hospital stay were 106±24 minutes and 5±3 days, respectively. These values are comparable with the procedure time and length of hospital stay reported in EVAR trials.22

EVAS with the Nellix device was designed to reduce complications, particularly endoleaks, and subsequent reinterventions during follow-up.23 We found that the use of the Nellix device was associated with a low rate of endoleak that is comparable to the reported rates of endoleak after EVAR.24 Type I endoleak was the most common type of endoleak reported by the included studies. In our study, the reported reintervention rate was low, ranging from 0% to 9.5% across 12 studies over a follow-up period of 5–23 months.

The impact of EVAS with the Nellix device on prevention of aneurysm sac enlargement has been promising based on the available evidence. Sac enlargement was reported in 10 out of 481 patients (with an incidence ranging from 0% to 5%) over a follow-up ranging from 12 to 23 months. The rates of aneurysm sac enlargement are generally lower than those reported following EVAR; aneurysm sac enlargement has been observed in 21%–42% of patients at 5 years following EVAR.25,26 However, differences in incidence of sac enlargement between studies reporting EVAS and those reporting EVAR may be related to differences in follow-up. Further studies are necessary to make direct comparison of outcomes between EVAS and EVAR.

Device migration is one of the notable complications that can occur post-EVAS.27 England et al reported a migration rate of up to 28%, none of which had associated clinical implications.27 In addition, Antoniou et al described a case of Nellix endograft migration with increasing sac diameter.28 In our study, we found a rate of migration ranging from 0% to 13% over a follow-up ranging from 5 to 23 months, highlighting the importance of surveillance after EVAS.

Most of the included patients had their aneurysm treated within the IFU 2013 of the Nellix device. Some studies reported clinical outcomes of aneurysm treatment within and beyond IFU 2013. Zerwes et al found no significant difference in technical success between patients treated within IFU and outside the IFU.10 Gossetti et al reported that patients treated outside the IFU had a statistically higher incidence of device-related complications.19 Comparative evidence is non-adherence to required to robustly evaluate complications associated with the recommended IFU of EVAS with the Nellix device.

The refined version of recommended IFU for the Nellix device was introduced in 2016.39 Zoethout et al compared 2-year clinical outcomes of patients treated within IFU 2013 and IFU 2016;21 they found less complications in the IFU 2016 group as compared to IFU 2013 group, although the difference was not significant.21 The authors suggested that the refined IFU 2016 did not clearly show better outcomes of the EVAS procedure as compared to IFU 2013. Furthermore, the applicability of Nellix has significantly reduced with IFU 2016. As the refined IFU are relatively new, further analysis and follow-up would be helpful to determine the impact of the new IFU on clinical outcomes.

Radiation exposure during EVAR poses a potential hazard toward patient safety.29,30 EVAS may have a benefit by exposing patients to less radiation compared to EVAR. The studies included in our review reported the fluoroscopy time; however, data on radiation exposure were not available. Ockert et al31 and Antoniou et al32 compared radiation exposure during EVAR and EVAS. The studies reported similar outcomes with reduced radiation exposure in EVAS compared to EVAR. This is beneficial to the patient as well as the theater team, in view of the well-recognized carcinogenic risk with radiation exposure; hence, it is worth further analysis.31

Aneurysm rupture after EVAS is a well-described complication. Antoniou et al reviewed late aneurysm ruptures after EVAR and noted that graft-related endoleaks are the predominant cause of rupture.33 In our study, a total of seven AAA ruptures were reported. Zerwes et al reported an early rupture of the aneurysm sac due to iatrogenic reason.10 The filling of the endobags had apparently caused the aortic rupture. This was not perceived during surgery. Computed tomography a week later showed retroperitoneal hematoma and a type Ia endoleak which was treated by implanting two additional Nellix endografts along with chimney grafts into both renal arteries. This allowed the endoleak to be successfully treated.10 Carpenter et al reported two late aneurysm ruptures, one iatrogenic and another one related to a type Ia endoleak.13 The first patient experienced multiple infections and rectal bleedings post-procedure. The Clinical Events Committee adjudicated the incident as a device-related bowel ischemia.13 The latter patient developed a type Ia endoleak 7 months after the procedure.13 This patient had the contained aneurysm rupture identified during open conversion and unfortunately died a month later.13 Thompson et al reported three aortic ruptures; one early rupture due to a type Ib endoleak and two late ruptures due to an untreated type Ia endoleak.16 These ruptures were treated with a distal extension and two conversions, respectively.16 Zoethout et al reported a rupture in a patient who previously had an unsuccessful Nellix-in-Nellix procedure.21 Aneurysm ruptures noted in our study were iatrogenic and endoleak related, in line with the findings of Antoniou et al.33 This further highlights the importance of surveillance and follow-up after EVAR.

Chimney EVAS (Ch-EVAS) is a newly described technique which was mentioned as an adjunctive procedure in two of the included studies.15,20 In both cases, Ch-EVAS was used to extend the proximal landing zone. Several studies have reported cases of patients treated with Ch-EVAS and analyzed clinical outcomes with encouraging results. Torella et al reported two cases where Ch-EVAS was successfully used to treat a failed EVAR and a juxtarenal aneurysm.34 Their study was further enhanced by Youssef et al reporting Ch-EVAS as a sensible treatment for failed EVAR due to endoleak.35 de Bruin et al also reported Ch-EVAS as a feasible solution for juxta and suprarenal aneurysms with adverse morphology, noting a low rate of endoleak over a short-term follow-up of a median 123 days.36 In a study with a larger cohort of patients, Thompson et al reported Ch-EVAS results from the ASCEND Registry and supported the use of Ch-EVAS in patients with complex aortic disease.37 Even though recent studies suggest encouraging results with Ch-EVAS to handle complex aneurysm morphology and persistent endoleaks from previous EVAR, further studies with larger patient cohorts and longer follow-up are essential to contribute to the knowledge regarding the durability and possible complications of Ch-EVAS.

Conclusion

Outcomes of EVAS are acceptable. Type I endoleak, sac enlargement, device migration, and aneurysm ruptured are the recognized complications. High-level research is required to investigate potential advantages of EVAS over conventional treatments.